TrialBlood cancer journal2021

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.

Benjamin A Derman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.